Overall | No AF progression | AF progression | p Value | |
---|---|---|---|---|
(N=6235) | (N=4756) | (N=1479) | ||
AF type | ||||
Paroxysmal | 76 | 77 | 70 | <0.0001 |
Persistent | 24 | 23 | 30 | |
Family history of AF | 15 | 15 | 15 | 0.53 |
Duration of AF diagnosis (months) | 42 (18–85) | 41 (17–82) | 49 (21–92) | <0.0001 |
AF on most recent ECG | 40 | 34 | 58 | <0.0001 |
EHRA symptom level | ||||
No symptoms | 36 | 34 | 39 | 0.0015 |
Mild | 47 | 47 | 44 | |
Severe | 15 | 16 | 14 | |
Disabling | 2.1 | 2.3 | 1.5 | |
CHADS2 risk groups | ||||
0 | 7.8 | 8.6 | 5.2 | <0.0001 |
1 | 24 | 24 | 22 | |
≥2 | 68 | 67 | 72 | |
Prior treatment | ||||
Oral anticoagulation therapy | 81 | 79 | 88 | <0.0001 |
Antiarrhythmic drug | 53 | 53 | 51 | 0.26 |
Prior cardioversions | 32 | 30 | 37 | <0.0001 |
Prior catheter ablation of AF | 7.2 | 7.7 | 5.5 | 0.0053 |
Current treatment | ||||
Oral anticoagulation therapy | 73 | 70 | 83 | <0.0001 |
β blockers | 63 | 62 | 66 | 0.0059 |
Calcium channel blockers | 30 | 30 | 32 | 0.29 |
Digoxin | 0 | 19 | 26 | <0.0001 |
Antiarrhythmic drug | 38 | 41 | 30 | <0.0001 |
Rhythm strategy | 42 | 44 | 34 | <0.0001 |
Continuous variables are presented as median and inter-quartile range.
AF, atrial fibrillation; EHRA, European Heart Rhythm Association.